Palisade Bio (PALI) Non Operating Income (2010 - 2026)
Palisade Bio (PALI) posted quarterly Non Operating Income of $1.1 million for Q1 2026, up 1335.0% year-over-year from $80000.0 in Q1 2025, and up 6.1% quarter-over-quarter from $1.1 million in Q4 2025.
Powered by 
Analysis
Palisade Bio (PALI) Non Operating Income (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Non Operating Income for 17 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income rose 1335.0% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $2.3 million (up 560.0% YoY), while the FY2025 annual figure was $1.3 million, up 202.85% from the prior year.
- Non Operating Income climbed to $1.1 million in Q1 2026 per PALI's latest filing, from $1.1 million in the prior quarter.
- Across five years, Non Operating Income topped out at $1.2 million in Q2 2022 and bottomed at -$317000.0 in Q1 2022.
- Historically, Non Operating Income has averaged $298529.4 across 5 years, with a median of $146000.0 in 2024.
- Annual changes were most pronounced in 2022 — Non Operating Income sank 97.49% — and 2025, when it soared 2747.37%.
- Palisade Bio's Non Operating Income stood at $128000.0 in 2022, then jumped by 42.97% to $183000.0 in 2023, then sank by 79.23% to $38000.0 in 2024, then jumped by 2747.37% to $1.1 million in 2025, then climbed by 6.1% to $1.1 million in 2026.
- Business Quant data shows PALI's Non Operating Income at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $54000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Palisade Bio | 440.73 Mn | 315.53 Mn | - | 1.12 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.12 Mn |
| Mar 31, 2026 | 1.15 Mn |
| Dec 31, 2025 | 1.08 Mn |
| Sep 30, 2025 | 54,000.00 |
| Jun 30, 2025 | 59,000.00 |
| Mar 31, 2025 | 80,000.00 |
| Dec 31, 2024 | 38,000.00 |
| Sep 30, 2024 | 106,000.00 |
| Jun 30, 2024 | 131,000.00 |
| Mar 31, 2024 | 146,000.00 |
| Dec 31, 2023 | 183,000.00 |
| Sep 30, 2023 | 182,000.00 |
| Jun 30, 2023 | 216,000.00 |
| Mar 31, 2023 | 189,000.00 |
| Dec 31, 2022 | 128,000.00 |
| Sep 30, 2022 | 422,000.00 |
| Jun 30, 2022 | 1.23 Mn |
| Mar 31, 2022 | -317,000.00 |
| Dec 31, 2021 | 5.10 Mn |
| Sep 30, 2021 | 11.10 Mn |